6uta
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='6uta' size='340' side='right'caption='[[6uta]], [[Resolution|resolution]] 3.10Å' scene=''> | <StructureSection load='6uta' size='340' side='right'caption='[[6uta]], [[Resolution|resolution]] 3.10Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'> | + | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6UTA OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6UTA FirstGlance]. <br> |
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.1Å</td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.1Å</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6uta FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6uta OCA], [https://pdbe.org/6uta PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6uta RCSB], [https://www.ebi.ac.uk/pdbsum/6uta PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6uta ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6uta FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6uta OCA], [https://pdbe.org/6uta PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6uta RCSB], [https://www.ebi.ac.uk/pdbsum/6uta PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6uta ProSAT]</span></td></tr> | ||
</table> | </table> | ||
- | == Function == | ||
- | [https://www.uniprot.org/uniprot/S6C4S0_HUMAN S6C4S0_HUMAN] | ||
- | <div style="background-color:#fffaf0;"> | ||
- | == Publication Abstract from PubMed == | ||
- | Recent epidemics demonstrate the global threat of Zika virus (ZIKV), a flavivirus transmitted by mosquitoes. Although infection is usually asymptomatic or mild, newborns of infected mothers can display severe symptoms, including neurodevelopmental abnormalities and microcephaly. Given the large-scale spread, symptom severity, and lack of treatment or prophylaxis, a safe and effective ZIKV vaccine is urgently needed. However, vaccine design is complicated by concern that elicited antibodies (Abs) may cross-react with other flaviviruses that share a similar envelope protein, such as dengue virus, West Nile virus, and yellow fever virus. This cross-reactivity may worsen symptoms of a subsequent infection through Ab-dependent enhancement. To better understand the neutralizing Ab response and risk of Ab-dependent enhancement, further information on germline Ab binding to ZIKV and the maturation process that gives rise to potently neutralizing Abs is needed. Here we use binding and structural studies to compare mature and inferred-germline Ab binding to envelope protein domain III of ZIKV and other flaviviruses. We show that affinity maturation of the light-chain variable domain is important for strong binding of the recurrent VH3-23/VK1-5 neutralizing Abs to ZIKV envelope protein domain III, and identify interacting residues that contribute to weak, cross-reactive binding to West Nile virus. These findings provide insight into the affinity maturation process and potential cross-reactivity of VH3-23/VK1-5 neutralizing Abs, informing precautions for protein-based vaccines designed to elicit germline versions of neutralizing Abs. | ||
- | |||
- | Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.,Esswein SR, Gristick HB, Jurado A, Peace A, Keeffe JR, Lee YE, Voll AV, Saeed M, Nussenzweig MC, Rice CM, Robbiani DF, MacDonald MR, Bjorkman PJ Proc Natl Acad Sci U S A. 2020 Apr 22. pii: 1919269117. doi:, 10.1073/pnas.1919269117. PMID:32321830<ref>PMID:32321830</ref> | ||
- | |||
- | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
- | </div> | ||
- | <div class="pdbe-citations 6uta" style="background-color:#fffaf0;"></div> | ||
==See Also== | ==See Also== | ||
*[[Antibody 3D structures|Antibody 3D structures]] | *[[Antibody 3D structures|Antibody 3D structures]] | ||
- | == References == | ||
- | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
- | [[Category: Zika virus ZIKV/H. sapiens/FrenchPolynesia/10087PF/2013]] | ||
[[Category: Bjorkman PJ]] | [[Category: Bjorkman PJ]] | ||
[[Category: Esswein SR]] | [[Category: Esswein SR]] | ||
[[Category: Gristick HB]] | [[Category: Gristick HB]] | ||
[[Category: Keeffe JR]] | [[Category: Keeffe JR]] |
Current revision
Crystal structure of Z004 iGL Fab in complex with ZIKV EDIII
|